Intra-Cellular Therapies Newsroom

Intra-Cellular Therapies Analyst Ratings

BenzingaJul 22 05:31 ET

Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $100

BenzingaJul 22 05:31 ET

Morgan Stanley Remains a Buy on Intra-Cellular Therapies (ITCI)

TipRanksJul 12 08:41 ET

Intra-Cellular Therapies (ITCI) Receives a Buy From RBC Capital

TipRanksJul 10 06:39 ET

Intra-Cellular Therapies Analyst Ratings

BenzingaJun 25 10:09 ET

Canaccord Genuity Adjusts Intra-Cellular Therapies Price Target to $113 From $107, Maintains Buy Rating

MT NewswiresJun 20 12:38 ET

Intra-Cellular Therapies Analyst Ratings

BenzingaJun 20 12:32 ET

Intra-Cellular Therapies Analyst Ratings

BenzingaJun 14 12:22 ET

Intra-Cellular Therapies Analyst Ratings

BenzingaJun 12 07:50 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Veeva Systems (VEEV), Intra-Cellular Therapies (ITCI) and Phreesia (PHR)

TipRanksMay 31 06:42 ET

Buy Rating Affirmed on Intra-Cellular Therapies Amid Strong Sales and Promising Clinical Trials

TipRanksMay 10 01:25 ET

Analyst Ratings For Intra-Cellular Therapies

BenzingaMay 8 16:00 ET

RBC Capital Remains a Buy on Intra-Cellular Therapies (ITCI)

TipRanksMay 8 06:40 ET

Intra-Cellular Therapies Analyst Ratings

BenzingaMay 8 05:42 ET

Intra-Cellular Therapies: A Hold Rating Amid Anticipation of Critical Phase 3 Data and Diverse Clinical Pipeline

TipRanksMay 7 14:30 ET

Buy Rating Affirmed: Intra-Cellular Therapies Exceeds Q1 Expectations With Caplyta Sales Surge

TipRanksMay 7 08:21 ET

Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $120 Price Target

BenzingaApr 24 09:58 ET

Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Intra-Cellular Therapies (ITCI)

TipRanksApr 24 08:55 ET

Intra-Cellular Therapies Analyst Ratings

BenzingaApr 23 12:02 ET

Buy Rating on Intra-Cellular Therapies as Caplyta Shows Promise in Major Depressive Disorder Market

TipRanksApr 22 10:11 ET